Lilly to begin rollout of Tempo Personalized Diabetes Management Platform.
Eli Lilly and Company will begin rollout of its first connected platform, the Tempo Personalized Diabetes Management Platform, later this year in the U.S. The technology aims to help adults living with type 1 or type 2 diabetes and clinicians make informed, data-backed decisions to manage treatment with Lilly insulins
The platform consists of three key components –i. the Tempo Smart Button; ii. a compatible app, TempoSmart; and iii. a prefilled insulin pen, Tempo Pen – which work together to deliver personalized guidance for adults with diabetes. The Smart Button was cleared by the FDA on September 16 2022. The compatible app was developed in partnership with Welldoc and is a private label iteration of the company's BlueStar, a diabetes management app, customized to receive insulin dose-related data from the Tempo Smart Button.
Healthcare providers will have access to a clinician hub, Tempo Insights, where they can access data shared by their patients through the app and track patients' progress.
"Despite technological advancements, people continue to experience challenges with the complexities of insulin dosing," said Kevin Cammack, Head of Connected Care, Lilly Diabetes. "Using the learnings from early adopters of Tempo, we look forward to continually innovating our technology to aid those who use Lilly insulins to manage their diabetes."
Adults with diabetes can access insulin dose information and advanced features through TempoSmart, including: i Medication reminders, personalized education resources and feedback on blood glucose levels. ii. Integration with Dexcom Continuous Glucose Monitoring (CGM) Systems via secondary display, as well as the Tempo Blood Glucose Monitor (BGM) and other compatible BGMs.iii. Compatibility to sync data with wearable devices from Fitbit, Garmin, Google Fit and the Apple Health app.
Lilly will conduct a phased rollout for the platform to select clinics starting later this year, followed by national availability targeted for 2023. The Tempo Pen is currently available for Lyumjev (insulin lispro-aabc) injection, 100 units/mL, Basaglar (insulin glargine) injection, 100 units/mL, and Humalog (insulin lispro injection) 100 units/mL. Lilly continues to work with Welldoc to integrate additional features for TempoSmart in future software updates.
Outside of the U.S., Lilly received CE (Conformité Européenne or European Conformity) marking certification for the Tempo Smart Button on 10 August 12022 and plans to begin small-scale pilots in selected countries through partnerships with existing diabetes management ecosystems.
Related news and insights
Fabhalta is a Factor B inhibitor that acts proximally in the alternative complement pathway of the immune system, providing comprehensive control of red blood cell (RBC) destruction within and outside the blood vessels (intra- and extravascular hemolysis [IVH and EVH])
Merck KGaA, a leading science and technology company, announced that its two Phase III EVOLUTION clinical trials (evolution RMS 1 and evolution RMS 2) investigating the efficacy and safety of evobrutinib did not meet their primary endpoints of reducing annualized relapse rates (ARR) in people with relapsing multiple sclerosis (RMS) compared to oral teriflunomide (Aubagio) (0.11 vs. 0.11 in evolution RMS 1 and 0.15 for evobrutinib vs. 0.14 for teriflunomide in evolution RMS 2, p=NS in both trials)